Eng-King Tan

1 month ago | nature.com | Bin Xiao |Eng-King Tan

A post hoc subgroup analysis has suggested potential therapeutic benefits of prasinezumab, a humanized monoclonal anti-α-synuclein antibody, in patients with rapidly progressing Parkinson’s disease (PD), despite initial trials showing limited impact on primary outcomes. Caution is needed due to the retrospective nature of subgroup analyses, and potential confounding factors that may have influenced the observed treatment effects in specific patient subsets. Critical considerations are provided here for designing and implementing preclinical studies and clinical trials involving monoclonal antibodies, suggesting that future research should prioritize refining preclinical models and optimizing biomarker-based patient selection to reduce risks of false trial outcomes, eventually advancing antibody-based therapies in PD effectively and safely.

Nov 20, 2024 | nature.com | Elaine Chew |Zheng Li |Michelle Lian |Vincent C. T. Mok |Clement C Tham |Mary B. Makarious | +5 more

AbstractParkinson’s disease (PD) is an incurable, progressive and common movement disorder that is increasing in incidence globally because of population aging. We hypothesized that the landscape of rare, protein-altering variants could provide further insights into disease pathogenesis. Here we performed whole-exome sequencing followed by gene-based tests on 4,298 PD cases and 5,512 controls of Asian ancestry.

Jun 4, 2024 | nature.com | Eng-King Tan

Dear editor,We read with interest the study by Zhong et al. [1], which studies the association between peripheral immunity and risk of incident brain disorders in a prospective cohort study of >160,000 participants from the UK Biobank. They found evidence of elevated peripheral innate immunity markers associated with an increased risk of neurological and psychiatric disorders. Interestingly, their findings of abnormal innate immunity are not specific to any neurological conditions.

Feb 28, 2024 | nature.com | Bin Xiao |Eng-King Tan

In two recent articles published in Nature Neuroscience and Cell, Nelson et al.1 and Chen et al.2 have shown that a rare APOE3 Christchurch (APOE3Ch) variant, R136S, has protective effects on neurodegeneration in various Alzheimer’s disease (AD) model systems through attenuating tau pathology and regulating its related neuroimmune responses. Nelson et al. and Chen et al.

Dec 12, 2023 | nature.com | Chao Deng |Chin-Hsien Lin |Bin Xiao |Eng-King Tan

AbstractRetinal thickness is related to Parkinson’s disease (PD), but its association with the severity of PD is still unclear. We conducted a Mendelian randomized (MR) study to explore the association between retinal thickness and PD.